NOVA subnet 68
NOVA, from Metanova Labs, is positioned as a biotech-oriented subnet for ML-driven drug screening. Public materials describe a network that applies global compute and competitive model work to large chemical search spaces, with validators running GPU-backed inference and scoring. The official framing supports drug-discovery acceleration and compound screening, not clinical validation.
About NOVA subnet 68
NOVA is a drug-discovery subnet using Bittensor incentives to coordinate machine-learning screening of chemical spaces.
Drug discovery requires costly screening across large chemical spaces, where faster model-driven search could improve early-stage candidate discovery.
Biotech researchers, computational chemistry teams, ML model developers, miners, validators, and decentralized science observers.
Team and ownership
Metanova Labs presents NOVA as its drug-discovery subnet. Micaela Bazo is the public founder or co-founder/CEO associated with the project, but detailed official biographies and locations are not available.
- Micaela Bazo, Founder / Co-founder and CEO, Metanova Labs
Key pages:
learn about Bittensor,
Bittensor glossary,
Bittensor FAQ,
Bittensor subnet screener,
portfolio tracker,
subnet baskets,
Neuralteq validator,
and fees.